Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06025630 · ClinicalTrials.gov registry record · Phase 1
Targeting Endoplasmic Reticulum Stress in Human Hypertension
A Phase 1 study of Hypertension, sponsored by University of North Texas Health Science Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06025630 is a Phase 1 study of Hypertension that is actively recruiting participants, run by University of North Texas Health Science Center. The registered enrollment target is 70 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06025630, a Phase 1 study of Hypertension, is actively recruiting participants, sponsored by University of North Texas Health Science Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TUDCA
Study Locations (1)
Texas
- University of North Texas Health Science Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06025630
The ClinicalTrials.gov registry entry for NCT06025630 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is University of North Texas Health Science Center, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06025630 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06025630 about?
NCT06025630 is a clinical study titled "Targeting Endoplasmic Reticulum Stress in Human Hypertension". There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in hum...
What is the current status of trial NCT06025630?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-08-15. Estimated completion is 2028-12-31.
What conditions does trial NCT06025630 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06025630?
The interventions under investigation include: Placebo (DRUG), TUDCA (DRUG).
Who is sponsoring clinical trial NCT06025630?
This trial is sponsored by University of North Texas Health Science Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06025630 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.